after a 6-week placebo and lipid-lowering diet run-in period, 159 male patients aged 21 to 55 years with type iia or iib hypercholesterolemia, low-density lipoprotein (ldl) cholesterol between 145 and 240 mg/dl, and normal basal levels of testosterone were randomly assigned to treatment with simvastatin 20 mg (n = 40), simvastatin 40 mg (n = 41), pravastatin 40 mg (n = 39), or placebo (n = 39) once daily.